1.Chan, WS, Dixon, ME. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008; 122: 289–90.
2.ACOG Committee Opinion no. 556. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 2013; 121: 887–90.
3.Canonico, M, Plu-Bureau, G, Scarabin, PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011; 70: 354–60.
4.Canonico, M. Hormone therapy and hemostasis among postmenopausal women: a review. Maturitas 2014; 21: 753–62.
5.Rosendaal, FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167–73.
6.Roach, RE, Lijfering, WM, van Hylckama Vlieg, A, et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 2013; 122: 4264–9.
7.Anderson, FA, Wheeler, HB, Goldberg, RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933–8.
8.White, RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14–8.
9.Tsai, AW, Cushman, M, Rosamond, WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182–9.
10.Cushman, M, Kuller, LH. Prentice, R, et al. Estrogen plus progestin and risk of venous thrombosis, JAMA 2004; 292: 1573–80.
11.Curb, JD, Prentice, RL, Bray, PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–80.
12.Ageno, W, Becattini, C, Brighton, T, Selby, S, Kamphuisen, PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93–102.
13.Alman-Farinelli, MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 8: 903–7.
14.Smith, NL, Blondon, M, Wiggins, KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA 2014; 174: 25–31.
15.Skouby, SO, Jespersen, J. Progestins in HRT: sufferance or desire? Maturitas 2009; 62: 371–5.
16.Smith, NL, Heckbert, SR, Lemaitre, RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581–7.
17.Skouby, SO, Sidelmann, J, Nilas, L, Gram, J, Jespersen, J. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. Climacteric 2008; 11: 489–97.
18.Canonico, M, Oger, E, Plu-Bureau, G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–5.
19.Blondon, M, Wiggins, KL, Van Hylckama Vlieg, A, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study. Br J Haematol 2013; 163: 418–20.
20.Eisenberger, A, Westhoff, C. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol 2014; 142: 76–82.
21.Hoibraaten, E, Qvigstad, E, Arnesen, H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961–7.
22.Reitsma, PH, Versteeg, HH, Middeldorp, S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012; 32: 563–8.
23.Conard, J, Basdevant, A, Thomas, JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995; 64: 957–62.
24.Lobo, RA, Bush, T, Carr, BR, Pickar, JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13–24.
25.Sidelmann, JJ, Skouby, SO, Kluft, C, et al. Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo. Thromb Res 2011; 128: e67–72.